---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-043706"
form_type: "8-K"
ticker: "IXHL"
cik: "0001873875"
company_name: "Incannex Healthcare Inc."
filed_at: "2025-05-15T23:59:59+00:00"
generated_at: "2026-05-21T05:48:41.292773+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Incannex Q3 FY2025 net loss $3.97M, cash $6.71M, IHL-42X Phase 2 dosing done

## Summary
- Net loss of $3.97M for quarter ended March 31, 2025, vs $6.03M same quarter last year.
- Cash and equivalents $6.71M as of March 31, up from $2.09M at Dec 31, 2024, after $12.5M private placement.
- Completed dosing of >120 patients in Phase 2 portion of RePOSA study for IHL-42X (OSA); topline data expected July 2025.
- Reported positive PK/safety study results for IHL-42X; both active components bioavailable, comparable to reference drugs.
- Formed OSA Clinical Advisory Board; appointed Alison Wimms (ResMed) as member.

## SEC filing metadata
- accession: 0001213900-25-043706
- form_type: 8-K
- ticker: IXHL
- cik: 0001873875
- company_name: Incannex Healthcare Inc.
- filed_at: 2025-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1873875/000121390025043706/0001213900-25-043706-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1873875/000121390025043706/ea0242329-8k_incannex.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-043706
- JSON: https://secwatch.observer/filing/0001213900-25-043706.json
- Plain text: https://secwatch.observer/filing/0001213900-25-043706.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.